WallStSmart

Clearpoint Neuro Inc (CLPT)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 51555% more annual revenue ($20.98B vs $40.61M). GEHC leads profitability with a 9.1% profit margin vs -71.6%. CLPT appears more attractively valued with a PEG of 0.61. GEHC earns a higher WallStSmart Score of 57/100 (C).

CLPT

Hold

37

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 6.3Quality: 5.0
Piotroski: 4/9Altman Z: -2.65

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CLPTUndervalued (+10.6%)

Margin of Safety

+10.6%

Fair Value

$14.96

Current Price

$12.89

$2.07 discount

UndervaluedFair: $14.96Overvalued

Intrinsic value data unavailable for GEHC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CLPT2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
42.9%10/10

Revenue surging 42.9% year-over-year

PEG RatioValuation
0.618/10

Growing faster than its price suggests

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Areas to Watch

CLPT4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$429.45M3/10

Smaller company, higher risk/reward

Price/BookValuation
20.5x2/10

Trading at 20.5x book value

Return on EquityProfitability
-154.3%2/10

ROE of -154.3% — below average capital efficiency

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.844/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CLPT

The strongest argument for CLPT centers on Revenue Growth, PEG Ratio. Revenue growth of 42.9% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bear Case : CLPT

The primary concerns for CLPT are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 3.37 is elevated, increasing financial risk.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

CLPT profiles as a hypergrowth stock while GEHC is a value play — different risk/reward profiles.

CLPT carries more volatility with a beta of 1.31 — expect wider price swings.

CLPT is growing revenue faster at 42.9% — sustainability is the question.

GEHC generates stronger free cash flow (112M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (57/100 vs 37/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Clearpoint Neuro Inc

HEALTHCARE · MEDICAL DEVICES · USA

ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.

Visit Website →

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?